Literature DB >> 16750633

Cachexia: lessons from melanocortin antagonism.

Mark D Deboer1, Daniel L Marks.   

Abstract

It is well established that disruptions in melanocortin signaling in the CNS result in morbid obesity, but only recently has evidence linked the activation of this system with the production of cachexia, also known as disease-associated wasting. Pro-opiomelanocortin-producing neurons, which express cytokine receptors, show increased activation in the presence of several cytokines that are increased in diseases that are associated with cachexia. Recent experiments show that blockade of melanocortin signaling using antagonists to the melanocortin MC(4) receptor attenuates disease-associated anorexia and wasting in rodent models of cancer and renal failure. This successful inhibition of cachexia is important because loss of appetite and lean body mass worsen the prognosis of many the diseases with which cachexia is associated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750633     DOI: 10.1016/j.tem.2006.05.005

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  16 in total

Review 1.  Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics.

Authors:  Ya-Xiong Tao
Journal:  Pharmacol Ther       Date:  2008-08-09       Impact factor: 12.310

2.  Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (cAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Robert C Speth; Adam T Zarth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2018-05-09       Impact factor: 7.446

Review 3.  The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: efficacy and mechanism.

Authors:  Mark D DeBoer
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.

Authors:  Ya-Xiong Tao
Journal:  Endocr Rev       Date:  2010-02-26       Impact factor: 19.871

5.  A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage.

Authors:  Cody J Lensing; Danielle N Adank; Stacey L Wilber; Katie T Freeman; Sathya M Schnell; Robert C Speth; Adam T Zarth; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2017-02-16       Impact factor: 4.418

Review 6.  Update on melanocortin interventions for cachexia: progress toward clinical application.

Authors:  Mark Daniel DeBoer
Journal:  Nutrition       Date:  2009-12-08       Impact factor: 4.008

7.  An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2016-03-29       Impact factor: 7.446

8.  Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile.

Authors:  Mark D Deboer; Xinxia Zhu; Peter R Levasseur; Akio Inui; Zhaoyong Hu; Guofeng Han; William E Mitch; John E Taylor; Heather A Halem; Jesse Z Dong; Rakesh Datta; Michael D Culler; Daniel L Marks
Journal:  Endocrinology       Date:  2007-11-26       Impact factor: 4.736

Review 9.  Cancer cachexia: medical management.

Authors:  Giovanni Mantovani; Clelia Madeddu
Journal:  Support Care Cancer       Date:  2009-08-18       Impact factor: 3.603

10.  Administration of IL-1beta to the 4th ventricle causes anorexia that is blocked by agouti-related peptide and that coincides with activation of tyrosine-hydroxylase neurons in the nucleus of the solitary tract.

Authors:  Mark D DeBoer; Jarrad M Scarlett; Peter R Levasseur; Wilmon F Grant; Daniel L Marks
Journal:  Peptides       Date:  2008-11-05       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.